Farmasulin H (human insulin) 100ME/ml. 3 ml. №5 cartridge


Manufacturer: Ukraine

Treatment of diabetic patients who need insulin to maintain normal glucose homeostasis.



Farmasulin H 3 ml Composition
active substance: human biosynthetic insulin (DNA recombinant);

1 ml of solution contains human biosynthetic insulin (recombinant DNA) 100 IU;

excipients: metacresol; glycerol; diluted hydrochloric acid or sodium hydroxide solution; water for injections.

Farmasulin H 3 ml Dosage form

Basic physical and chemical properties: clear, colorless liquid.

Farmasulin H 3 ml Pharmacotherapeutic group
Antidiabetic drugs. Insulin preparations. Insulins and short-acting analogues. ATX code А10А В01.

Farmasulin H is a short-acting insulin preparation.

The main action of insulin is to regulate glucose metabolism. In addition, insulin affects several anabolic and anti-catabolic processes in various tissues. In muscle tissue, these effects include increased synthesis of glycogen, fatty acids, glycerol, and protein, as well as increased absorption of amino acids while suppressing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism, and amino acid release.

The figure below shows a typical insulin activity profile (glucose utilization curve) as a bold line after subcutaneous injection. Possible variability in the duration of insulin activity and / or its intensity in different patients is depicted as a shaded area in the graph. Individual variability depends on factors such as dose volume, temperature at the injection site, and the patient’s level of physical activity.

The drug Farmasulin H is a human insulin that is produced using technologies using recombinant DNA.

The pharmacokinetics of insulin do not reflect the metabolic activity of the hormone. Therefore, when considering the question of insulin activity, it will be more expedient to study the glucose utilization curves (given above).

During the toxicological studies, no serious harmful effects associated with the use of the drug were identified.

Treatment of diabetic patients who need insulin to maintain normal glucose homeostasis.

Hypoglycemia. Hypersensitivity to the active substance and to any excipients of the drug, with the exception of cases of the use of desensitizing therapy.

Interaction with other medicinal products and other types of interactions
Some drugs affect glucose metabolism, so you should consult your doctor about taking any other drugs with human insulin. The physician should take into account possible interactions if the patient is taking any medications.

The need for insulin may increase with the use of drugs with hyperglycemic activity, such as glucocorticoids, thyroid hormones and growth hormone, danazol, β2-sympathomimetics (for example, ritodrin, salbutamol, terbutaline), thiazides.

The need for insulin may decrease with the use of drugs with hypoglycemic activity, such as oral hypoglycemic drugs, salicylates (for example, acetylsalicylic acid), some antidepressants (monoamine oxidase inhibitors), some angiotensin-converting enzyme inhibitors (captopril, β-receptor blockers, nonselectives), -blockers or alcohol.

Somatostatin analogs (octreotide, lanreotide) can both increase and decrease the need for insulin.